EGFR and familial pancreatic carcinoma: Like many chemotherapeutic agents, the effectiveness of EGFR inhibitors have been approved by Food and Drug Administration for use in several tumor cases, alone and in combination with gemcitabine for pancreatic cancer [57,58].